Business
Press Release Sep 07 2022
Zydus Lifesciences Limited has informed the Exchange about press release dated 07-Sep-2022 titled Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS)
About this update from Zydus Lifesciences Limited
[{"type":"text","content":" Zydus Lifesciences Limited has informed the Exchange about press release dated 07-Sep-2022 titled Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS) View Attachment","length":390,"tagName":"div"}]